Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Averting Hiv Infections In New York City: A Modeling Approach Estimating The Future Impact Of Additional Behavioral And Biomedical Hiv Prevention Strategies, Jason Kessler, Julie E. Myers, Kimberly A. Nucifora, Nana Mensah, Alexis Kowalski, Monica Sweeney, Christopher Toohey, Amin Khademi, Colin Shepard, Blayne Cutler, R. Scott Braithwaite
Averting Hiv Infections In New York City: A Modeling Approach Estimating The Future Impact Of Additional Behavioral And Biomedical Hiv Prevention Strategies, Jason Kessler, Julie E. Myers, Kimberly A. Nucifora, Nana Mensah, Alexis Kowalski, Monica Sweeney, Christopher Toohey, Amin Khademi, Colin Shepard, Blayne Cutler, R. Scott Braithwaite
Amin Khademi
Background: New York City (NYC) remains an epicenter of the HIV epidemic in the United States. Given the variety of evidence-based HIV prevention strategies available and the significant resources required to implement each of them, comparative studies are needed to identify how to maximize the number of HIV cases prevented most economically.
Methods: A new model of HIV disease transmission was developed integrating information from a previously validated micro-simulation HIV disease progression model. Specification and parameterization of the model and its inputs, including the intervention portfolio, intervention effects and costs were conducted through a collaborative process between the academic modeling …
Should Expectations About The Rate Of New Antiretroviral Drug Development Impact The Timing Of Hiv Treatment Initiation And Expectations About Treatment Benefits?, Amin Khademi, R. Scott Braithwaite, Denis Saure, Andrew J. Schaefer, Kimberly Nucifora, Mark S. Roberts
Should Expectations About The Rate Of New Antiretroviral Drug Development Impact The Timing Of Hiv Treatment Initiation And Expectations About Treatment Benefits?, Amin Khademi, R. Scott Braithwaite, Denis Saure, Andrew J. Schaefer, Kimberly Nucifora, Mark S. Roberts
Amin Khademi
Background: Many analyses of HIV treatment decisions assume a fixed formulary of HIV drugs. However, new drugs are approved nearly twice a year, and the rate of availability of new drugs may affect treatment decisions, particularly when to initiate antiretroviral therapy (ART).
Objectives: To determine the impact of considering the availability of new drugs on the optimal initiation criteria for ART and outcomes in patients with HIV/AIDS.
Methods: We enhanced a previously described simulation model of the optimal time to initiate ART to incorporate the rate of availability of new antiviral drugs. We assumed that the future rate of availability …